Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cladribine + pantoprazole
- Development stage
- Phase 1
- Lead developer
- Merck KGaA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of cladribine, a purine nucleoside analog used for treating relapsing forms of multiple sclerosis, and pantoprazole, a proton pump inhibitor. The combination has been specifically studied to assess potential drug-drug interactions, particularly whether pantoprazole's effect on gastric pH might alter cladribine's oral bioavailability. Clinical studies have shown that coadministration of pantoprazole with cladribine tablets had no significant effect on the rate and extent of cladribine absorption.
02
Targets
Beyond the preview
Go deeper on cladribine + pantoprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cladribine + pantoprazole.